Merck drug approval
January 15, 2014
A NOVEL antiplatelet agent
vorapaxar, a thrombin receptor
antagonist, should be approved,
a preliminary review of data has
found.
The US Food and Drug
Administration (FDA) said Merck
& Co Inc’s drug, with the brand
name Zontivity, had had “robustly
positive” clinical trials, Reuters
reported.
Medical experts were expected
to recommend whether the
drug should be approved or not
tomorrow, with the FDA generally
following suit, the publication
reported.
To read more CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jan 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jan 14